Ken Miller Named Chief Commercial Officer at KORU Medical Systems

KORU Medical Systems Inc. has appointed Ken Miller as chief commercial officer (CCO).
 
Miller has more than 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing strategy, international expansion, and driving sustainable growth and profitability. As CCO, he will have oversight of the company’s global commercial function including U.S. and international sales and marketing organizations. He joins KORU Medical with impressive medical device and pharmaceutical industry experience, most recently from NASCO Healthcare, where he spent five years as president and CEO. At NASCO, Miller transformed sales and marketing, and led the consolidation of NASCO’s manufacturing footprint, which delivered year-over-year double digit revenue and EBITDA growth.

Prior to NASCO, Miller spent seven years at Becton Dickinson; his last role there was worldwide president, Diabetes Care, where he led the transition from a product focus to a full-service diabetes management solution provider. Miller also held leadership roles in marketing, sales, and business development with Novo Nordisk, Adams Respiratory Therapeutics, and Roche Laboratories. He earned his bachelor of arts degree in business management from State University of New York at Albany and his MBA from The University of Chicago, Booth School of Business.
 
“I am confident Ken’s experience in healthcare paired with his track record of success will be instrumental in propelling KORU Medical in this next phase of our growth. His arrival comes at an exciting time in our company’s journey and his commercialization expertise, drive and passion for customers and innovation will be instrumental in achieving this next stage of our success,” KORU Medical President/CEO Linda Tharby said. “I am grateful to have Ken’s leadership on the KORU Medical team as we continue to grow the business in new markets and geographies and execute on our strategic growth plan.”
 
In connection with the start of his employment, Miller was awarded two separate options, each to purchase 200,000 shares of the company’s common stock. One of the option awards is subject to a four-year vesting schedule with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in equal annual installments on the subsequent three anniversaries. The other of the option awards is subject to vesting based on specified net sales growth targets for each of the 2024 through 2026 fiscal years, which will vest in full upon the company maintaining a specified run rate for at least two consecutive quarters after Jan. 1, 2024. 

“I am thrilled to have been appointed chief commercial officer of KORU Medical, and eager to ramp up and accomplish our strategic goals and deliver value to the company and its shareholders,” Miller stated. “I selected KORU Medical because of the solutions it provides patients in need, its innovation efforts to continually improve its products, its current leadership position in subcutaneous infusion and the enormous potential of the markets served.”
 
KORU Medical Systems develops, manufactures, and commercializes subcutaneous drug delivery systems that improve quality of life for patients worldwide. The FREEDOM Syringe Infusion System currently includes the FREEDOM60 and FreedomEdge Syringe Infusion Drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. These devices are used for infusions administered in the home and alternate care settings.